Search

Your search keyword '"Thijs, Judith L"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Thijs, Judith L" Remove constraint Author: "Thijs, Judith L"
170 results on '"Thijs, Judith L"'

Search Results

4. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

12. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

13. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts

14. Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters

15. Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

16. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

17. Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

18. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis

19. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

20. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

21. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers

22. EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

23. Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

25. Een baby met uitgebreide blaren aan handen en voeten

26. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

27. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

28. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

29. Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

30. Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

32. Endotypes in constitutioneel eczeem

33. Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

35. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity

37. Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment

38. Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity

40. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A

45. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy

46. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease

47. Endotypes in constitutioneel eczeem

48. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

50. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

Catalog

Books, media, physical & digital resources